# US Gamma Knife Market

> US Gamma Knife Market Research Report: Size, Share, Trend Analysis By Disease Indication (Brain Metastasis, Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, Others) and By Anatomy (Head, Neck, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.41%
- **2024:** $ 140 Million
- **2025:** $ 147.57 Million
- **2035:** $ 250 Million
- **Key Players:** Elekta AB (SE), Accuray Incorporated (US), Varian Medical Systems (US), Brainlab AG (DE), MediTech (US), Nicolet Biomedical (US), Shenzhen Huikang Medical (CN), Stereotactic Radiosurgery (US)

**Report ID:** MRFR/HC/51019-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-gamma-knife-market-52779

---

## Market Summary

## **US Gamma Knife Market Overview**

As per MRFR analysis, the US Gamma Knife Market Size was estimated at 111.79 (USD Million) in 2024.The US Gamma Knife Market Industry is expected to grow from 120(USD Million) in 202 to 210 (USD Million) by 2035. The US Gamma Knife Market CAGR (growth rate) is expected to be around 5.219% during the forecast period (2025 - 2035)

**Key US Gamma Knife Market Trends Highlighted**

The US Gamma Knife Market is witnessing a notable shift due to advancements in technology and growing precision in neurosurgery. The increasing prevalence of brain tumors and other neurological disorders is driving demand for non-invasive treatment options, which Gamma Knife radiosurgery provides. Moreover, an aging population in the U.S. is contributing to a rise in neurological conditions, escalating the need for effective treatment solutions. As healthcare providers focus on optimizing patient outcomes, there is a growing trend towards utilizing Gamma Knife for its accuracy and reduced side effects compared to traditional surgery.

Opportunities in the U.S. market are expanding as more healthcare facilities incorporate Gamma Knife technology into their treatment offerings. Innovations in imaging techniques and improved software for treatment planning are creating pathways for enhanced precision in targeting tumors. As hospitals and outpatient centers look to provide comprehensive cancer care, investing in advanced Gamma Knife systems represents a strategic opportunity to attract patients seeking specialized treatment options. Additionally, the trend of collaborative care amongst healthcare providers is promoting multi-disciplinary approaches to treatment, further cementing the role of Gamma Knife in patient management.

In recent times, the market has also seen a rise in the adoption of outpatient treatment models. This trend is driven by an increasing preference for cost-effective, less invasive solutions that allow patients to return home the same day as the procedure. The favorable reimbursement landscape in the U.S. is playing a vital role in shaping the market as well, enabling more facilities to offer these advanced treatment modalities. Overall, the US Gamma Knife Market is evolving with technological advancements and changing patient care models, promising significant developments in the future.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**US Gamma Knife Market Drivers**

**Increasing Prevalence of Cancer Cases**

The US Gamma Knife Market Industry is experiencing growth due to the increasing prevalence of cancer cases in the United States. The American Cancer Society estimates that there will be approximately 1.9 million new cancer cases diagnosed in 2021 alone. As cancer rates continue to rise, the demand for non-invasive treatment options like the Gamma Knife is anticipated to grow. Notably, the National Cancer Institute has reported that the survival rate for certain cancers has improved due to advancements in treatment technologies, including stereotactic radiosurgery, a method commonly used with Gamma Knife systems.

This trend highlights the vital role of advanced radiation therapy in enhancing patient outcomes, further driving the market expansion. Furthermore, with the aging population in the U.S., which, according to the U.S. Census Bureau reports, is projected to reach 70 million older adults by 2030, there will be an increased demand for effective cancer treatment solutions, solidifying the key growth drivers for the US Gamma Knife Market Industry.

**Technological Advancements in Medical Equipment**

The US Gamma Knife Market Industry is driven by rapid technological advancements in medical equipment, particularly in the precision and capability of Gamma Knife systems. Innovations such as improved imaging techniques, enhanced treatment planning software, and higher precision delivery systems boost the efficacy of treatment. For instance, the integration of MRI and CT imaging with Gamma Knife technology has significantly increased the accuracy of tumor targeting. The Food and Drug Administration in the U.S. continues to approve new technologies that improve the effectiveness and safety of these devices, fueling market growth.

Recent developments in artificial intelligence and machine learning also promise to further enhance the capabilities of these systems, creating a competitive market landscape that is poised for continued growth in the coming years.

**Government Support and Funding for Cancer Treatment**

Government initiatives aimed at improving cancer treatment options significantly drive the US Gamma Knife Market Industry. Federal and state programs provide funding for research and development (R&D) as well as for hospitals to acquire state-of-the-art treatment technologies. The National Institutes of Health, for example, has increased its budget for cancer research, allocating over 6 billion USD annually towards studies focused on innovative treatment technologies, including advanced radiation therapies. In addition, the Medicare and Medicaid expansion for services that include Gamma Knife treatment enables patient access. This motivates healthcare facilities to adopt new technologies for treatment.

The government endorsement is essential here because it not only subsidizes capitalist growth stimuli but also guarantees the market, in this case, healthcare providers and patients, the financial resources needed to sustain the use of Gamma Knife technology.

**Growing Awareness Among Patients and Healthcare Providers**

The awareness of non-invasive treatment options among patients and healthcare providers is steadily increasing, driving the growth of the US Gamma Knife Market Industry. Campaigns led by organizations such as the American Society for Radiation Oncology aim to educate the public about treatment options for brain tumors and other conditions. As patients become more educated about their treatment choices, they increasingly advocate for advanced technologies, significantly impacting their treatment decisions. This heightened awareness is coupled with more healthcare professionals receiving training in Gamma Knife technology, which expands the application of this treatment method.

The result is a growing refocusing within clinical practices towards modern, minimally invasive procedures, which naturally elevates the demand for Gamma Knife services, ensuring sustained market growth and expansion in the US Gamma Knife Market Industry.

**US Gamma Knife Market Segment Insights**

**Gamma Knife Market Disease Indication Insights**

The Disease Indication segment within the US Gamma Knife Market comprises critical areas such as Brain Metastasis, Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, and others. The US Gamma Knife Market revenue is influenced significantly by the rising prevalence of brain-related disorders among the population, which demonstrates a steady demand for advanced treatment options like stereotactic radiosurgery. Brain Metastasis has emerged as a major focus area in this segment due to its increasing occurrence as a complication in patients with systemic cancer, necessitating precise and effective treatment technologies.

The importance of Cancer as a disease indication is underscored by the growing awareness and urgency for innovative therapies, driven by the increase in cancer cases across the United States, thereby positioning Gamma Knife treatments as vital solutions in oncological care. Arteriovenous Malformation, known for its complex treatment pathways, also plays a significant role within this segment, as the effectiveness of Gamma Knife procedures offers efficient and less invasive options for patients.

Additionally, Trigeminal Neuralgia, a debilitating condition characterized by severe facial pain, further highlights the market's expansion due to the need for specialized, targeted therapies that Gamma Knife technology provides. These insights reflect the dynamic nature of the US Gamma Knife Market industry, where each disease indication presents unique challenges and growth opportunities. The market's ability to leverage cutting-edge technology to address these conditions contributes to the overall advancement in healthcare. The segmentation within the US Gamma Knife Market data provides a detailed overview of how targeted treatment options can enhance patient outcomes and improve quality of life.

As healthcare continues to evolve, the need for specialized treatment modalities in these areas ensures that the Gamma Knife remains at the forefront of neurosurgical advancement, driving sustained interest and investment in the sector. Market trends are also leaning towards personalized medicine, giving each of these conditions their unique significance and positioning within the overall framework of the US Gamma Knife Market statistics. The continued development and refinement of these technologies promise to not only cater to the current needs in the Disease Indication segment but also anticipate future challenges in brain treatment methodologies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Gamma Knife Market Anatomy Insights**

The US Gamma Knife Market has shown notable segmentation, particularly within the Anatomy category that encompasses Head, Neck, and other regions. The prominence of the Head segment is attributed to the increasing incidence of brain tumors and other neurological disorders, making it a vital area of focus for treatment options such as stereotactic radiosurgery. Meanwhile, the Neck segment plays a crucial role, particularly in addressing tumors and conditions affecting nearby anatomical structures. As the population ages and the prevalence of such medical conditions rises, the demand for effective treatment solutions in these areas grows, driving market dynamics.

Additionally, advancements in technology and procedural techniques in the Gamma Knife Market provide opportunities for improved efficacy and patient outcomes. The ongoing research and development initiatives in the U.S. enhance the market landscape, fostering innovations that will shape the future of radiation therapy. The segmentation reflects the broader need for targeted and effective treatments, making it an essential component of the overall US Gamma Knife Market statistics and facilitating tailored therapeutic approaches for patients.

**US Gamma Knife Market Key Players and Competitive Insights**

The US Gamma Knife Market is characterized by a rapidly evolving landscape where advanced technologies and innovative treatments are driving competition among players seeking a foothold in this specialized sector. The market encompasses various stakeholders, including manufacturers, healthcare providers, and research institutions, all of whom contribute to the growth and advancement of Gamma Knife surgical systems that are designed for non-invasive treatment of neurological conditions.

Key trends impacting the market include increased patient demand for precise treatments, a growing prevalence of cancer and other neurological disorders, as well as significant investments in research and development aimed at enhancing the efficacy and safety of Gamma Knife technologies. Competitive dynamics are influenced by both established healthcare technology companies and emerging players that strive to differentiate their offerings through quality, technological advancements, and collaborative partnerships. Toshiba Medical Systems holds a notable position in the US Gamma Knife Market thanks to its strong focus on innovative imaging solutions and patient-centric technologies.

The company is recognized for its advanced imaging systems that integrate seamlessly with Gamma Knife treatments, thereby enabling more accurate targeting and improved treatment outcomes. With a commitment to enhancing the capabilities of healthcare professionals, Toshiba Medical Systems emphasizes a robust portfolio that includes cutting-edge imaging modalities, which serve as valuable adjuncts to Gamma Knife procedures. Their established relationships with leading healthcare institutions, coupled with a strong distribution network, enhance their market presence, allowing them to cater effectively to the needs of medical professionals and patients alike.

This focus on quality and innovation has enabled Toshiba Medical Systems to maintain a competitive edge within the market, positioning it as a preferred choice among healthcare providers. NeuroLogica presents a compelling presence in the US Gamma Knife Market through its commitment to developing portable, high-quality imaging systems that cater specifically to the needs of neurological applications. The company is known for its unique range of products, which includes advanced mobile CT scanners that can enhance surgical capabilities and facilitate improved workflow in clinical settings.

NeuroLogica's strengths lie in its innovative approach to imaging technology, which emphasizes convenience and efficiency, allowing for more accurate diagnoses and treatments in challenging clinical environments. With strategic mergers and acquisitions, NeuroLogica has bolstered its technological capabilities and market share, enabling it to offer tailored solutions that resonate with healthcare providers aiming for excellence in patient care. The company's focus on research and collaboration within the U.S. healthcare landscape further solidifies its role as a key player in the Gamma Knife market, fostering advancements that enhance treatment modalities and patient outcomes.

**Key Companies in the US Gamma Knife Market Include**

**US Gamma Knife Market Industry Developments**

Recent developments in the US Gamma Knife Market highlight significant advancements and investments among key players. Notably, in September 2023, Accuray announced an expansion of its radiation therapy solutions, aimed at enhancing precision treatment for patients with brain tumors. Similarly, Elekta introduced innovative software enhancements to optimize treatment planning and patient workflow for Gamma Knife procedures. Furthermore, in July 2023, General Electric and Philips Healthcare collaborated to enhance imaging technologies, improving the integration of diagnostic and treatment modalities in Gamma Knife applications.

In terms of Mergers and Acquisitions, November 2022 saw Varian Medical Systems acquire the assets of a leading software company to bolster its portfolio in image-guided radiation therapy, a move that could strengthen its Gamma Knife offerings. The US Gamma Knife Market has experienced growth due to rising incidences of brain disorders, with multiple companies, including Brainlab and Stereotactic Brain Perfusion, innovating their product lines to meet advanced patient care standards. Over the past three years, the market has noticeably expanded, driven by technological innovations and partnerships among leading companies, establishing a robust landscape in the realm of stereotactic radiosurgery.

**Gamma Knife Market Segmentation Insights**

**Gamma Knife Market Disease Indication Outlook**

- 

**Gamma Knife Market Anatomy Outlook**

-

## Market Drivers

### Supportive Reimbursement Policies

Supportive reimbursement policies are playing a pivotal role in the growth of the gamma knife market. Insurance coverage for gamma knife procedures is becoming more prevalent, as payers recognize the cost-effectiveness and clinical benefits of this treatment modality. The Centers for Medicare & Medicaid Services (CMS) have established reimbursement frameworks that facilitate access to gamma knife treatments for patients. This financial support encourages healthcare providers to invest in gamma knife technology, knowing that they will be compensated for the services rendered. As reimbursement policies continue to evolve in favor of advanced treatment options, the gamma knife market is expected to thrive, driven by increased accessibility and affordability for patients.

### Rising Incidence of Brain Disorders

The gamma knife market is experiencing growth due to the increasing incidence of brain disorders such as tumors and vascular malformations. According to the National Cancer Institute, brain tumors account for approximately 1.4% of all cancers in the US, with an estimated 24,000 new cases diagnosed annually. This rising prevalence necessitates advanced treatment options, positioning gamma knife technology as a preferred choice for patients and healthcare providers. The non-invasive nature of gamma knife procedures, coupled with their effectiveness in targeting tumors, enhances their appeal in the gamma knife market. As more healthcare facilities adopt this technology, the market is likely to expand, driven by the need for efficient and effective treatment modalities for brain disorders.

### Increased Awareness of Treatment Options

Awareness regarding advanced treatment options for brain disorders is rising among patients and healthcare professionals, positively impacting the gamma knife market. Educational initiatives and outreach programs by medical associations are informing the public about the benefits of non-invasive treatments. As patients become more informed, they are more likely to seek out gamma knife procedures, which are known for their precision and minimal recovery time. This shift in patient behavior is likely to drive demand for gamma knife technology, as healthcare providers respond to the growing interest in effective treatment alternatives. Consequently, the gamma knife market is expected to benefit from this heightened awareness and patient engagement.

### Technological Innovations in Radiation Therapy

Technological innovations in radiation therapy are significantly influencing the gamma knife market. Advances in imaging techniques and treatment planning software have enhanced the precision and effectiveness of gamma knife procedures. For instance, the integration of MRI and CT imaging allows for better tumor localization, improving treatment outcomes. The market is witnessing the introduction of new gamma knife models that offer enhanced features, such as real-time imaging and adaptive treatment planning. These innovations not only improve patient safety but also increase the efficiency of treatment delivery, making gamma knife technology more attractive to healthcare providers. As a result, the gamma knife market is likely to expand as these technological advancements continue to evolve.

### Growing Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is a crucial driver for the gamma knife market. The US government and private sector are increasingly allocating funds to enhance healthcare facilities, particularly in neurosurgery and oncology departments. Reports indicate that healthcare spending in the US is projected to reach $6 trillion by 2027, with a significant portion directed towards advanced medical technologies. This investment facilitates the acquisition of gamma knife systems, which are essential for providing cutting-edge treatment options. As hospitals and clinics upgrade their equipment to meet patient demand, the gamma knife market is poised for growth, reflecting the broader trend of modernization in healthcare infrastructure.

## Future Outlook

The [Gamma Knife Market](https://www.marketresearchfuture.com/reports/gamma-knife-market-19189) is projected to grow at 5.41% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising healthcare expenditure.

**New opportunities:**

- Expansion of telemedicine services for remote consultations Development of advanced imaging integration with gamma knife systems Partnerships with insurance providers for enhanced reimbursement models

By 2035, the gamma knife market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Disease Indication: Brain Metastasis (Largest) vs. Trigeminal Neuralgia (Fastest-Growing)

The US gamma knife market is witnessing significant market share distribution among various disease indications. Brain Metastasis stands as the largest segment, driven by the rising prevalence of metastatic cancer in the brain, accounting for a substantial percentage of procedures performed. Other segments such as Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, and Others are also contributing to the market dynamics, albeit at varying scales of share and growth potential.

Growth trends within this segment are largely influenced by advancements in gamma knife technology, which enhance treatment efficacy and patient outcomes. The increasing awareness and adoption of non-invasive treatment methods further stimulate demand. Furthermore, Trigeminal Neuralgia is emerging as the fastest-growing segment due to heightened recognition of its impact, driving the need for effective and precise treatment options in the market.

Brain Metastasis (Dominant) vs. Trigeminal Neuralgia (Emerging)

Brain Metastasis is characterized by the infiltration of cancer cells from other parts of the body into the brain, making it a critical and dominant indication in the gamma knife segment. Patients with this condition typically require targeted therapies that minimize damage to surrounding healthy tissue, something that gamma knife radiosurgery excels at providing. In contrast, Trigeminal Neuralgia is gaining traction as an emerging indication, as its significant impact on the quality of life prompts increased clinical attention. New innovative techniques in gamma knife treatment are making it more accessible for managing Trigeminal Neuralgia, thus expanding its share in the market and highlighting the growing demand for effective pain management solutions.

### By Anatomy: Head (Largest) vs. Neck (Fastest-Growing)

In the US gamma knife market, the distribution of market share among the anatomy segments reveals that the Head segment holds the largest share, largely due to its prevalent usage in treating brain tumors and other neurological conditions. The Neck segment, while smaller, is gaining traction as more clinicians recognize the effectiveness of gamma knife technology for conditions affecting this area, contributing to its increasing market presence.

Growth trends indicate a notable shift towards the Neck segment, which is seeing a rise in demand driven by advancements in medical technologies and an increase in patient awareness. As healthcare providers expand their applications of gamma knife technology, particularly for metastatic lesions and functional disorders in the neck, this segment is projected to be the fastest-growing. This shift signifies a broader acceptance and recognition of the versatility of gamma knife treatments beyond traditional uses.

Head (Dominant) vs. Neck (Emerging)

The Head segment of the US gamma knife market is characterized by its dominance owing to the high incidence of brain-related conditions, necessitating precise and effective treatment methodologies. This segment benefits from established protocols and a robust foundation of clinical research supporting gamma knife procedures. Conversely, the Neck segment is emerging as a vital player, driven by advancements that allow for more effective treatments of complex conditions in this area. While still in a growth phase, increasing clinical trials and positive patient outcomes are bolstering its position, attracting both clinical interest and investment. The innovative approaches within neck treatments signify a dynamic shift in treatment paradigms, promising to enhance patient care and broaden the market scope in the coming years.

## Competitive Benchmarking

The gamma knife market exhibits a dynamic competitive landscape characterized by rapid technological advancements and a growing emphasis on precision medicine. Key players such as Elekta AB (SE), Accuray Incorporated (US), and Varian Medical Systems (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Elekta AB (SE) focuses on expanding its product portfolio through continuous research and development, while Accuray Incorporated (US) emphasizes the integration of artificial intelligence (AI) in its treatment planning systems. Varian Medical Systems (US) is actively pursuing collaborations with healthcare providers to improve patient outcomes, thereby shaping a competitive environment that prioritizes technological sophistication and patient-centric solutions.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Elekta, Accuray, and Varian creates a competitive atmosphere where innovation and strategic positioning are paramount.
In October Elekta AB (SE) announced a partnership with a leading healthcare institution to develop a next-generation gamma knife system that incorporates advanced imaging technologies. This strategic move is likely to enhance Elekta's product offerings and solidify its position as a leader in the market, as it aligns with the growing demand for precision in stereotactic radiosurgery.
In September Accuray Incorporated (US) launched a new AI-driven software platform designed to streamline treatment planning for gamma knife procedures. This initiative not only reflects Accuray's commitment to innovation but also positions the company to meet the increasing expectations of healthcare providers for efficiency and accuracy in treatment delivery.
In August Varian Medical Systems (US) expanded its collaboration with a prominent research university to explore the integration of machine learning algorithms in gamma knife treatments. This partnership is indicative of Varian's strategic focus on harnessing cutting-edge technology to improve treatment efficacy and patient outcomes, thereby enhancing its competitive edge in the market.
As of November current trends in the gamma knife market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing operational capabilities. The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, reliability in supply chains, and the ability to deliver superior patient care. This shift underscores the importance of innovation as a critical driver of success in the gamma knife market.

## Recent News & Developments

Recent developments in the US Gamma Knife Market highlight significant advancements and investments among key players. Notably, in September 2023, Accuray announced an expansion of its radiation therapy solutions, aimed at enhancing precision treatment for patients with brain tumors. Similarly, Elekta introduced innovative software enhancements to optimize treatment planning and patient workflow for Gamma Knife procedures. Furthermore, in July 2023, General Electric and Philips Healthcare collaborated to enhance imaging technologies, improving the integration of diagnostic and treatment modalities in Gamma Knife applications.

In terms of Mergers and Acquisitions, November 2022 saw Varian Medical Systems acquire the assets of a leading software company to bolster its portfolio in image-guided radiation therapy, a move that could strengthen its Gamma Knife offerings. The US Gamma Knife Market has experienced growth due to rising incidences of brain disorders, with multiple companies, including Brainlab and Stereotactic Brain Perfusion, innovating their product lines to meet advanced patient care standards. Over the past three years, the market has noticeably expanded, driven by technological innovations and partnerships among leading companies, establishing a robust landscape in the realm of stereotactic radiosurgery.

## Report Scope

| MARKET SIZE 2024 | 140.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 147.57(USD Million) |
| MARKET SIZE 2035 | 250.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.41% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Elekta AB (SE), Accuray Incorporated (US), Varian Medical Systems (US), Brainlab AG (DE), MediTech (US), Nicolet Biomedical (US), Shenzhen Huikang Medical (CN), Stereotactic Radiosurgery (US) |
| Segments Covered | Disease Indication, Anatomy |
| Key Market Opportunities | Advancements in precision targeting technologies enhance treatment efficacy in the gamma knife market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth in the gamma knife market, enhancing treatment options and patient outcomes. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US gamma knife market in 2024?**
A: The market valuation of the US gamma knife market was $140.0 Million in 2024.

**Q: What is the projected market valuation for the US gamma knife market in 2035?**
A: The projected market valuation for the US gamma knife market is $250.0 Million in 2035.

**Q: What is the expected CAGR for the US gamma knife market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US gamma knife market during the forecast period 2025 - 2035 is 5.41%.

**Q: Which companies are considered key players in the US gamma knife market?**
A: Key players in the US gamma knife market include Elekta AB, Accuray Incorporated, Varian Medical Systems, Brainlab AG, MediTech, Nicolet Biomedical, Shenzhen Huikang Medical, and Stereotactic Radiosurgery.

**Q: What are the primary disease indications for gamma knife treatments?**
A: The primary disease indications for gamma knife treatments include Brain Metastasis, Cancer, Arteriovenous Malformation, Trigeminal Neuralgia, and Others.

**Q: What was the market value for cancer treatment using gamma knife in 2024?**
A: The market value for cancer treatment using gamma knife was $50.0 Million to $90.0 Million in 2024.

**Q: How does the market value for brain metastasis compare to other disease indications?**
A: The market value for brain metastasis ranged from $30.0 Million to $55.0 Million, indicating a competitive position among other disease indications.

**Q: What anatomical areas are primarily targeted in gamma knife procedures?**
A: The primary anatomical areas targeted in gamma knife procedures include the Head, Neck, and Others.

**Q: What was the market value for neck treatments in 2024?**
A: The market value for neck treatments using gamma knife was $40.0 Million to $75.0 Million in 2024.

**Q: What is the anticipated growth trend for the US gamma knife market?**
A: The anticipated growth trend for the US gamma knife market suggests a steady increase, with a projected valuation of $250.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-gamma-knife-market-52779*